Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02900664
Title A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals

colorectal cancer

lung non-small cell carcinoma

triple-receptor negative breast cancer


Nazartinib + Spartalizumab

CJM112 + Spartalizumab

Spartalizumab + Trametinib

Canakinumab + Spartalizumab


Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN | BEL

No variant requirements are available.